Pfizer Ltd
Pfizer Ltd is engaged in manufacturing, marketing, trading and export of pharmaceutical products. It manufactures products through its own facility and also has various independent contract/ third party manufacturers based across the country and sells its products through independent distributors primarily in India.[1]
It is the 3rd largest multinational pharmaceutical company in India.[2]
- Market Cap ₹ 23,906 Cr.
- Current Price ₹ 5,226
- High / Low ₹ 6,453 / 3,950
- Stock P/E 156
- Book Value ₹ 302
- Dividend Yield 0.67 %
- ROCE 27.2 %
- ROE 19.8 %
- Face Value ₹ 10.0
Pros
- Company is almost debt free.
- Company has been maintaining a healthy dividend payout of 33.2%
Cons
- Stock is trading at 17.3 times its book value
- Earnings include an other income of Rs.512 Cr.
- Working capital days have increased from 60.8 days to 135 days
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Pharmaceuticals Industry: Pharmaceuticals - Multinational
Part of BSE 250 SmallCap Index BSE 400 MidSmallCap Index Nifty 500 Multicap 50:25:25 BSE Allcap BSE SmallCap
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
| Operating Profit |
| OPM % |
| Interest |
| Depreciation |
| Profit before tax |
| Tax % |
| EPS in Rs |
| Raw PDF |
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
| Nov 2006 | Nov 2007 | Nov 2008 | |
|---|---|---|---|
| 664 | 676 | 678 | |
| 537 | 815 | 760 | |
| Operating Profit | 127 | -139 | -82 |
| OPM % | 19% | -21% | -12% |
| 48 | 600 | 512 | |
| Interest | 0 | 0 | 0 |
| Depreciation | 13 | 10 | 11 |
| Profit before tax | 163 | 451 | 419 |
| Tax % | 35% | 25% | 29% |
| 106 | 340 | 300 | |
| EPS in Rs | 35.64 | 113.94 | 100.39 |
| Dividend Payout % | 63% | 24% | 12% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | 0% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | 6% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 11% |
| 5 Years: | 5% |
| 3 Years: | 2% |
| 1 Year: | 28% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| Last Year: | 20% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
| Nov 2006 | Nov 2007 | Nov 2008 | |
|---|---|---|---|
| Equity Capital | 30 | 30 | 30 |
| Reserves | 376 | 620 | 871 |
| 0 | 0 | 0 | |
| 240 | 218 | 197 | |
| Total Liabilities | 646 | 867 | 1,098 |
| 65 | 60 | 51 | |
| CWIP | 2 | 10 | 32 |
| Investments | 0 | 0 | 0 |
| 579 | 797 | 1,014 | |
| Total Assets | 646 | 867 | 1,098 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
| Nov 2006 | Nov 2007 | Nov 2008 | |
|---|---|---|---|
| 123 | 17 | 238 | |
| 7 | 232 | -79 | |
| -34 | -76 | -95 | |
| Net Cash Flow | 97 | 173 | 64 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
| Nov 2006 | Nov 2007 | Nov 2008 | |
|---|---|---|---|
| Debtor Days | 38 | 33 | 32 |
| Inventory Days | 160 | 149 | 190 |
| Days Payable | 208 | 144 | 164 |
| Cash Conversion Cycle | -10 | 39 | 58 |
| Working Capital Days | 2 | 45 | 135 |
| ROCE % | 37% | 27% |
Documents
Announcements
- Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate 19 Nov
-
Announcement under Regulation 30 (LODR)-Change in Management
14 Nov - Appointment of Mr. Chetan Solse as India Legal Lead.
- Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate 12 Nov
-
Announcement under Regulation 30 (LODR)-Change in Directorate
10 Nov - Completion of terms for two Independent Directors.
- Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate 7 Nov
Annual reports
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from nse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2012
from nse
Concalls
-
Aug 2020TranscriptPPT
-
May 2017TranscriptPPT
-
Feb 2017TranscriptPPT
-
Nov 2016TranscriptPPT
-
Aug 2016TranscriptPPT
-
May 2016TranscriptPPT
-
Feb 2016TranscriptPPT
Product Portfolio
Presently, the company sells ~150 different products across 15+ therapeutic areas viz. anti-allergic, anti-diabetic, anti-infectives, cardiovascular, gastrointestinal, neurology, pain, respiratory, vitamin/minerals, antibiotics, etc.[1][2]